Proteomics in clinical interventions: achievements and limitations in biomarker development.
Development of toxicological and clinical biomarkers for disease diagnosis, quantification of toxicant/drug responses and rapid patient care are major concerns in modern biology. Even after human genome sequencing, identification of specific molecular signatures for unambiguous correlation with toxicity and clinical interventions is a challenging task. Differential protein expression patterns and protein-protein interaction studies have started unraveling rigorous molecular explanation of multi-factorial and toxicant borne diseases. Proteome profiling is extensively used to investigate etiology of diseases, develop predictive biomarkers for toxicity and therapeutic interventions and potential strategies for treatment of complex and toxicant mediated diseases. In this review, achievements and limitations of proteomics in developing predictive biomarkers for toxicological and clinical interventions have been discussed.
Sinha
Ashima
A
Industrial Toxicology Research Centre, Lucknow-226 001, India.
Singh
Chetna
C
Parmar
Devendra
D
Singh
Mahendra Pratap
MP
D000818:Animals; D015415:Biomarkers; D003933:Diagnosis; D006801:Humans; D011041:Poisoning / Q000175:diagnosis / Q000628:therapy; D011237:Predictive Value of Tests; D040901:Proteomics; D014116:Toxicology
D015415:Biomarkers